Table 1.
Patient clinical characteristics in CPFE
| Survivors (n=26) | Non-survivors (n=67) | p Value | |
| Age, year (mean) | 73.19±1.18 (57–84) | 73.83±7.07 (56–91) | 0.5815 |
| Male sex, % | 85 | 81 | 0.6570 |
| Pack-year | 60±22.0 (5–110) | 64±31.4 (0–180) | 0.5754 |
| mMRC scale | 2.6±0.88 (1–4) | 2.5±0.93 (1–4) | 0.5091 |
| Dyspnoea duration, months | 11.04±5.73 (0–18) | 13.07±14.20 (0–96) | 0.4821 |
| Clubbing, % | 12 | 55 | <0.0001 |
| KL-6, IU/l | 852±278 (505–1200) | 1174±725 (201–4250) | 0.0413 |
| Systolic PAP, mm Hg | 45 | 75 | <0.0001 |
| Baseline FEV1, % | 71.14±8.72 (59.6–103.9) | 70.88±9.25 (31.4–106.3) | 0.9128 |
| Baseline FVC, % | 68.52±9.09 (57–99.7) | 61.89±9.48 (24.9–82.3) | 0.0058 |
| HOT, % | 12 | 43 | 0.0035 |
| Paraseptal emphysema, % | 19 | 69 | <0.0001 |
| Acute exacerbation, n (%) | 0 (0) | 22 (32) | 0.0007 |
| %FEV1/%FVC >1.2, % | 19 | 79 | <0.0001 |
| Cancer, % | 0 | 18 | 0.1068 |
| Cardiovascular, % | 27 | 40 | 0.2339 |
| Ejection fraction, % | 58.2±3.90 | 56.9±5.19 | 0.2337 |
| Survival time, months | 50.16±17.79 (26–96) | 25.68±21.54 (1–98) | <0.0001 |
Data are presented as mean±SD and mean %predicted ± SD.
CPFE, combined pulmonary fibrosis and emphysema; FEV1, forced expired volume in one second; %FEV1, per cent predicted forced expired volume in one second; FVC, forced vital capacity; HOT, Home Oxygen Therapy; IPF, idiopathic pulmonary fibrosis; mMRC, modified Medical Research Council; NSIP, non-specific interstitial pneumonia.